{"product_id":"b0gnpw2rbw","title":"BioLionaire Scientist—Volume 3: RNA EMPIRE: The Business of RNA Platforms Turning RNA Into Scalable Enterprises","description":"\u003cp\u003eRNA Empire  examines the transformation of RNA from a molecular intermediary into one of the most powerful therapeutic platforms in modern biotechnology.\u003c\/p\u003e\n\n\u003cp\u003eFrom messenger RNA vaccines to gene silencing technologies, aptamers, circular RNA, and the convergence of CRISPR with RNA systems, this volume explores how RNA became programmable infrastructure. It analyzes the scientific breakthroughs that made RNA medicines possible, the delivery systems that enabled clinical translation, and the platform strategies that turned RNA into a scalable enterprise.\u003c\/p\u003e\n\n\u003cp\u003eRather than presenting RNA as a single technological wave, this book frames it as an ecosystem — where molecular engineering, lipid nanoparticle delivery, manufacturing scalability, regulatory navigation, and funding strategy determine long-term dominance.\u003c\/p\u003e\n\n\u003cp\u003eWritten for scientists, translational researchers, founders, and biotech strategists,  RNA Empire  connects mechanism with monetization and discovery with durable platform building.\u003c\/p\u003e\n\n\u003cp\u003eWho This Book Is For This volume is written for graduate students, postdoctoral researchers, clinician-scientists, RNA biologists, biotech founders, translational teams, and innovation-driven institutions seeking a rigorous understanding of RNA platform strategy. It is also appropriate for academic libraries and biotechnology incubators focused on next-generation therapeutics.\u003c\/p\u003e\n\n\u003cp\u003eTable of Contents Part I - The Science of RNA\u003cbr\u003e\nChapter 1 — RNA: The Unsung Architect of Life\u003cbr\u003e\nChapter 2 — The RNA Toolbox\u003cbr\u003e\nChapter 3 — How mRNA Became a Medicine\u003c\/p\u003e\n\n\u003cp\u003ePart II - RNA Therapeutics\u003cbr\u003e\nChapter 4 — RNA Delivery Systems\u003cbr\u003e\nChapter 5 — mRNA Therapeutics: Vaccines \u0026amp; Beyond\u003cbr\u003e\nChapter 6 — mRNA Interference \u0026amp; Gene Silencing\u003cbr\u003e\nChapter 7 — Aptamers: The Nucleic-Acid Antibodies\u003cbr\u003e\nChapter 8 — CRISPR Meets RNA\u003cbr\u003e\nChapter 9 — Cell-Free RNA Manufacturing\u003cbr\u003e\nChapter 10— Circular RNA \u0026amp; Next-Gen RNA Drugs\u003c\/p\u003e\n\n\u003cp\u003ePart III - RNA Industry\u003cbr\u003e\nChapter 11 — RNA-Based Therapeutic Platforms\u003cbr\u003e\nChapter 12 — BioLionaire Roadmap in the RNA Age\u003c\/p\u003e\n\n\u003cp\u003eAppendices\u003cbr\u003e\nAppendix A — NIH SBIR Phase I Proposal Roadmap\u003cbr\u003e\nAppendix B — Example (II) SBIR Phase I Grant Proposal\u003c\/p\u003e\n\n\u003cp\u003eGlossary\u003cbr\u003e\nIndex\u003cbr\u003e\nCompanies Discussed in this Volume\u003cbr\u003e\nEssential Reading\u003c\/p\u003e","brand":"ANT","offers":[{"title":"Ebook","offer_id":67975248052260,"sku":"YSL61436","price":5.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0805\/2614\/7620\/files\/71AjgyxOqHL._SY1500.jpg?v=1793603709","url":"https:\/\/booktavero.com\/products\/b0gnpw2rbw","provider":"BookTavero","version":"1.0","type":"link"}